Satyajit Nanda

Satyajit Nanda is a Doctoral Researcher at Ludwig-Maximilians-Universität München, focusing on advancements in Viral Immunology and monoclonal antibody-based therapies, and also serves as a Scientific Researcher at Fraunhofer-Gesellschaft, specializing in the development of viral recombinant proteins. Previously, Satyajit worked as a Visiting Scientist at TWINCORE GmbH, where the focus was on monoclonal antibody blocking of SARS-CoV-2 infection. As a Vaccine Production Biologist at Enzene Biosciences Ltd, responsibilities included recovery and purification process development for monoclonal antibody production. Satyajit also conducted an M.Sc dissertation project at the National Institute of Technology, Rourkela, investigating plant-derived drugs on mitophagy in cancer therapy. Satyajit holds a Master's degree in Biotechnology from Ravenshaw University and a Bachelor's degree in Biology with a chemistry major from Utkal University.